Treatment of post-bariatric hypoglycemia with exendin (9-39)
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsTracey L. MCLAUGHLIN, Colleen M. CRAIG
Life of this patent
Estimating the term…
Abstract
Compositions and methods for treating hyperinsulinemic hypoglycemia, such as hyperinsulinemic hypoglycemia after bariatric surgery, are provided. In some embodiments, an effective amount of the glucagon-like peptide-1 receptor antagonist exendin(9-39) is subcutaneously administered twice per day.
Claims16
A method for treating or preventing hyperinsulinemic hypoglycemia in a patient, the method comprising subcutaneous administration of a composition comprising a therapeutically effective amount of exendin(9-39), wherein the composition is administered in a volume of 0.25 mL to 2 mL.
2-9. (canceled)
11-12. (canceled)
15-31. (canceled)
Dependencies are inferred from the claim text.